RPG Life Sciences to Acquire API Business of Raghava Life Sciences for ₹135 Crore
RPG Life Sciences' subsidiary will acquire the API and Intermediates Business of Raghava Life Sciences for up to ₹135 Crore via slump sale. The acquired business had revenues of ₹19 Crore in FY26 and includes manufacturing facilities and 29 API molecules. The deal is expected to close within 30 days.
The acquisition involves a significant consideration of ₹135 Crore and expands the company's API business, which could have a notable impact on its overall operations and market position.
The acquisition is a strategic move to expand the company's API business, which is positive for future growth.
RPG Life Sciences Limited announced that its wholly-owned subsidiary, RPG Active Pharma Limited, will acquire the Active Pharmaceutical Ingredients (APIs) and Intermediates Businesses of Raghava Life Sciences Private Limited through a Business Transfer Agreement (BTA) via a slump sale. This strategic acquisition is in line with RPG Life Sciences' goal to expand its API business.
The business being acquired includes revenues of approximately ₹19 Crore in FY26 (unaudited), manufacturing facilities, an R&D facility, and a portfolio of 29 API molecules, of which 22 are commercialized and 7 are under development. Raghava Life Sciences Private Limited also operates in Contract Research Organization (CRO) and Contract Research and Manufacturing Services (CRAMS) business, which is not part of this transaction.
The total consideration for the acquisition is up to ₹135 Crore, subject to customary adjustments and applicable taxes. The transaction is expected to be completed within 30 days, contingent on the satisfaction of closing conditions and regulatory approvals.
The Board of Directors of RPG Life Sciences Limited approved the execution of the BTA during their meeting held on September 2, 2026, which commenced at 7:00 pm and concluded at 8:10 pm. The Promoter/Promoter Group/Group Companies of RPG Life Sciences have no interest in Raghava Life Sciences Private Limited.
A plain-language summary of a public exchange filing by RPG Life Sciences Limited. Read the original for the full detail.